For Immediate Release

Contact: Brian Hansen
Total Site, Inc.
303-415-9404
bhansen@totalsite.com

Denver Pharmaceutical Company Launches Web Site
Investor Information and Research Highlighted

BOULDER, CO - Allos Therapeutics announces the launch of its corporate web site, http://www.allos.com. The site serves as an informational tool for investors and users interested in cancer treatments.

Allos is focused on developing and commercializing innovative small molecule drugs, initially for improving cancer treatments. Most of the company's research and development has been earmarked for the drug RSR13, a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen carrying protein contained within red blood cells. The Allos web site contains sections devoted to RSR13's applications and the clinical trials that support them.

The Investor Relations section of the web site contains extensive information on the company's financial status. Potential investors can obtain data on stock quotes, SEC filings, cash flow and more. Users can also get snapshot biographies of key employees within the corporate governance.

Allos looked to Boulder-based web developer, Total Site, Inc. to produce its internet presence. After successfully transferring the allos.com domain to a new hosting company, Total Site was able to give its client an effective, professional web site. Allos.com also required the successful integration of its off-site email news service product with the new design.

With extensive experience helping companies to shape their web identity, Total Site has been able to capitalize on the recent influx of high-tech and bio-tech companies in Colorado's Front Range region. In addition to corporate web design, Total Site, http://www.totalsite.com, offers ecommerce solutions, web application development, internet marketing and email management.